These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22217438)

  • 1. Asenapine: a clinical overview.
    Potkin SG
    J Clin Psychiatry; 2011; 72 Suppl 1():14-8. PubMed ID: 22217438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
    Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
    J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
    Citrome L
    Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asenapine: a new antipsychotic option.
    Henry JM; Fuller MA
    J Pharm Pract; 2011 Oct; 24(5):447-51. PubMed ID: 22156709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asenapine-Induced Acute Dystonia in an Adolescent Male.
    Bhuyan D; Ghosh S; Bhattacharya A; Praharaj SK
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):955-956. PubMed ID: 27154343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
    Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
    Kane JM; Mackle M; Snow-Adami L; Zhao J; Szegedi A; Panagides J
    J Clin Psychiatry; 2011 Mar; 72(3):349-55. PubMed ID: 21367356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the clinical efficacy of asenapine in schizophrenia.
    Minassian A; Young JW
    Expert Opin Pharmacother; 2010 Aug; 11(12):2107-15. PubMed ID: 20642375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asenapine review, part II: clinical efficacy, safety and tolerability.
    Citrome L
    Expert Opin Drug Saf; 2014 Jun; 13(6):803-30. PubMed ID: 24793161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.
    Schoemaker J; Stet L; Vrijland P; Naber D; Panagides J; Emsley R
    Pharmacopsychiatry; 2012 Jul; 45(5):196-203. PubMed ID: 22454251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder.
    Med Lett Drugs Ther; 2010 Feb; 52(1331):9-10. PubMed ID: 20216523
    [No Abstract]   [Full Text] [Related]  

  • 13. Allergic reactions and sudden death with asenapine.
    Masters KJ
    J Clin Psychiatry; 2012 May; 73(5):720; author reply 720-1. PubMed ID: 22697198
    [No Abstract]   [Full Text] [Related]  

  • 14. Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice.
    Fagiolini A; Forgione RN; Morana B; Maccari M; Goracci A; Bossini L; Pellegrini F; Cuomo A; Casamassima F
    Expert Opin Pharmacother; 2013 Mar; 14(4):489-504. PubMed ID: 23356509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asenapine.
    Weber J; McCormack PL
    CNS Drugs; 2009 Sep; 23(9):781-92. PubMed ID: 19689168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
    Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
    CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.
    Stepanova E; Grant B; Findling RL
    Paediatr Drugs; 2018 Apr; 20(2):121-134. PubMed ID: 29170943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
    Kinoshita T; Bai YM; Kim JH; Miyake M; Oshima N
    Psychopharmacology (Berl); 2016 Jul; 233(14):2663-74. PubMed ID: 27271087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asenapine: a clinical review of a second-generation antipsychotic.
    Stoner SC; Pace HA
    Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.
    Chapel S; Hutmacher MM; Haig G; Bockbrader H; de Greef R; Preskorn SH; Lalonde RL
    J Clin Pharmacol; 2009 Nov; 49(11):1297-308. PubMed ID: 19843656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.